An endoscopically placed bypass liner significantly improves glycemic control and weight loss in patients with poorly controlled type 2 diabetes and obesity.

• HbA1c reduction at 12 months was -1.10% for the bypass group versus -0.28% for sham (p=0.0004).
• Patients in the bypass group experienced a 7.7% total weight loss compared to 2.1% in the sham group (p<0.0001).

Consider this device for patients struggling with both diabetes management and obesity; it shows potential for better surgical outcomes and patient quality of life.

• 28.3% of the bypass group achieved HbA1c ≤ 7% compared to 9.4% in the sham group (p<0.0003).